Key result
DOACs treat ~39% of acute pulmonary thromboembolism in Turkey, predominantly driven by rivaroxaban.
Why the study?
Although phase 3 studies reported that direct oral anticoagulants are at least as effective as warfarin for acute pulmonary thromboembolism, up-to-date real-life data on their prescription frequency and outcomes in Turkey were lacking.
What is the real-world frequency of direct oral anticoagulant usage, reasons for preference, and associated bleeding rate among patients treated for acute pulmonary thromboembolism in Turkey?
Cross-Sectional (n=836)
Yes
What is the real-world frequency of direct oral anticoagulant usage, reasons for preference, and associated bleeding rate among patients treated for acute pulmonary thromboembolism in Turkey?
This multicenter Turkish real-world survey demonstrates that DOACs—predominantly rivaroxaban—are prescribed in 38.5% of acute pulmonary thromboembolism patients, primarily following failure to maintain target INR on warfarin, with a low 4% bleeding rate.
Answers are grounded in this paper and cite their sources.
Informs regional DOAC prescribing for acute PE; leaves open comparative effectiveness versus warfarin in non-Western populations.
Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary. Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results. Study Design: Cross-sectional study. Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially. Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients. Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice.
No takes yet. Share an insight, caveat, or question.
Tanrıverdi et al. (2021) conducted a cross-sectional in Acute pulmonary thromboembolism (PTE) (n=836). Direct oral anticoagulants (DOACs: rivaroxaban, apixaban, dabigatran, edoxaban) vs. Conventional anticoagulant therapy (warfarin or low molecular weight heparin) was evaluated on Frequency of DOAC usage in acute pulmonary thromboembolism treatment. Direct oral anticoagulants were used in 38.5% of patients with acute pulmonary thromboembolism in Turkey, with rivaroxaban being the most preferred agent and bleeding occurring in 4% of users.
Synapse has enriched 10 related papers. Consider them for comparative context: